NXL · XBRL financial data
Nexalin Technology financial statements, every fiscal year
The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (NXL's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Revenue | 1,321 | 111 | 169 | 302 |
| Cost of revenue | 363 | 26 | 37 | 61 |
| Gross profit | 958 | 85 | 132 | 240 |
| Research and development | 511 | 1,922 | 1,191 | 1,084 |
| Selling, general and administrative | 1,492 | 3,819 | 4,229 | 4,398 |
| General and administrative | — | 2,368 | 2,553 | 3,133 |
| Total operating expenses | 2,791 | 5,781 | 7,887 | 8,631 |
| Operating income (loss) | (1,833) | (5,696) | (7,755) | (8,391) |
| Interest expense | 59 | 39 | (3) | (8) |
| Net income (loss) | (1,698) | (4,649) | (7,607) | (8,222) |
| Earnings per share, basic USD per share | (0.30) | (0.63) | (0.83) | (0.50) |
| Earnings per share, diluted USD per share | (0.30) | (0.63) | (0.83) | (0.50) |
| Weighted average shares, basic thousands of shares | 5,572 | 7,357 | 9,216 | 16,392 |
| Weighted average shares, diluted thousands of shares | 5,572 | 7,357 | 9,216 | 16,392 |
Balance sheet
CSVFiscal years (NXL's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | 163 | 580 | 574 | 655 |
| Short-term investments | 6,831 | 2,368 | 2,905 | 3,068 |
| Accounts receivable | 5 | 9 | 13 | 82 |
| Inventory | 154 | 156 | 175 | 131 |
| Prepaid and other current assets | 272 | 316 | 294 | 363 |
| Total current assets | 7,425 | 3,430 | 3,961 | 4,299 |
| Property and equipment, net | 1 | — | — | — |
| Right-of-use asset | 6 | 0 | — | — |
| Total assets | 7,432 | 3,632 | 4,223 | 4,635 |
| Accounts payable | 658 | 160 | 156 | 245 |
| Accrued liabilities | 540 | 261 | 391 | 643 |
| Total current liabilities | 1,949 | 425 | 547 | 887 |
| Lease liability, non-current | 4 | — | — | — |
| Total liabilities | 1,953 | 425 | 547 | 887 |
| Accumulated deficit | (72,389) | (77,038) | (84,645) | (92,867) |
| Total stockholders' equity | 5,479 | 3,207 | 3,676 | 3,748 |
| Total liabilities and equity | 7,432 | 3,632 | 4,223 | 4,635 |
| Common shares outstanding (cover page) thousands of shares | 7,287 | 7,437 | 13,304 | 20,582 |
Cash flows
CSVFiscal years (NXL's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Net income (loss) | (1,698) | (4,649) | (7,607) | (8,222) |
| Stock-based compensation | 271 | 2,413 | 3,561 | 3,123 |
| Net cash from operating activities | (2,216) | (3,835) | (3,944) | (4,958) |
| Net cash from investing activities | (6,795) | 4,453 | (578) | (132) |
| Proceeds from issuing common stock | 8,545 | — | 4,516 | 4,646 |
| Net cash from financing activities | 8,512 | (200) | 4,516 | 5,170 |
Compare with peers
SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Nexalin Technology | 1,005 | 12 | (1,802)* | 22.0M | 0.6 quarters | 10-QJun 30, 2026 |
| Iridex | 4,680 | 12,566 | 174* | 17.6M | — | 10-QJul 4, 2026 |
| Beyond Air | 5,509 | 1,768 | (4,946) | 957,631 | 2.0 quarters | 10-QJun 30, 2026 |
| RetinalGenix Technologies | 27 | not reported | (137)* | 18.8M | 0.2 quarters | 10-QJun 30, 2026 |
| Harvard Apparatus Regenerative Technology | 351 | 414 | (569)* | 17.6M | 0.6 quarters | 10-QJun 30, 2026 |
| Biotricity | 467 | 4,277 | 507 | 19.9M | — | 10-QJun 30, 2026 |
| VASO | 38,291 | not reported | 17,444* | 176.0M | — | 10-QJun 30, 2026 |
| Envoy Medical | 19,679 | 51 | (5,456)* | 77.2M | 3.6 quarters | 10-QJun 30, 2026 |
| PetVivo Holdings | 123 | 338 | (966) | 38.0M | 0.1 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.